Vitamin e and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 2, 2013, Pages 134-143

  Hoofnagle, J H ^a   Van Natta, M L ^b   Kleiner, D E ^c   Clark, J M ^b   Kowdley, K V ^d   Loomba, R ^e   Neuschwander Tetri, B A ^f   Sanyal, A J ^g   Tonascia, J ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAINT LOUIS UNIVERSITY   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIOXIDANT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; ENZYMOLOGY; FATTY LIVER; MIDDLE AGED;

ADULT; ALANINE TRANSAMINASE; ANTIOXIDANTS; FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; THIAZOLIDINEDIONES; VITAMIN E; WEIGHT LOSS;

EID: 84879242918     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12352     Document Type: Article

References (27)

1. Traber MG, Stevens JF,. Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med 2011; 51: 1000-13.
2. Kowdley KV, Mason JB, Meydani SN, Cornwall S, Grand RJ,. Vitamin E deficiency and impaired cellular immunity related to intestinal fat malabsorption. Gastroenterology 1992; 102: 2139-42.
3. Tanyel MC, Mancano LD,. Neurologic findings in vitamin E deficiency. Am Fam Physician 1997; 55: 197-201.
4. Sokol RJ, Balistreri WF, Hoofnagle JH, Jones EA,. Vitamin E deficiency in adults with chronic liver disease. Am J Clin Nutr 1985; 41: 66-72.
5. Lee IM, Cook NR, Gaziano JM, et al,. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 56-65.
6. Lonn E, Bosch J, Yusuf S, et al. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 1338-47.
7. Lippman SM, Klein EA, Goodman PJ, et al,. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
8. Gaziano JM, Glynn RJ, Christen WG, et al,. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301: 52-62.
9. Sano M, Ernesto C, Thomas RG, et al,. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-22.
10. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E,. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
11. Lavine JE,. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
12. Sanyal AJ, Mofrad PS, Contos MJ, et al,. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.
13. Sanyal AJ, Chalasani N, Kowdley KV, et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
14. Lavine JE, Schwimmer JB, Van Natta ML, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-68.
15. Chalasani NP, Sanyal AJ, Kowdley KV, et al. NASH CRN Research Group. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009; 30: 88-96.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
17. Wanless IR, Lentz JS,. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
18. Williams CD, Stengel J, Asike MI, et al,. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
19. Vernon G, Baranova A, Younossi ZM,. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
20. Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE,. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 13-24.
21. Adams LA, Lymp JF, St Sauver J, et al,. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
22. Rafiq N, Bai C, Fang Y, et al,. Long-term follow up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-8.
23. Ekstedt M, Franzén LE, Mathiesen UL, et al,. Long term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
24. Södenberg C, Stål P, Askling J, et al,. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
25. Charlton M, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA,. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-53.
26. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-24.
27. Wong VW-S, Wong GL-H, Tsang SW-C, et al,. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009; 29: 387-96. Diseases Diseases Diseases Diseases Diseases Diseases Diseases Diseases Diseases